Alexandre Challine

Alexandre Challine

Auto-generated profile, based on publicly available information

Alexandre Challine

Department of Digestive Surgery, AP-HP, Hôpital Saint Antoine, Paris, France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
ABAneel Bhangu
Aneel Bhangu
AAAdesoji O Ademuyiwa
Adesoji O Ademuyiwa
MAMaria Lorena Aguilera
Maria Lorena Aguilera
PAPhilip Alexander
Philip Alexander
SASara W Al-Saqqa
Sara W Al-Saqqa
RBRuth Blanco
Ruth Blanco
Surgical site infection (SSI) is one of the most common infections associated with health care, but its importance as a global health priority is not fully understood. We quantified the burden of SSI after gastrointestinal surgery in countries in all parts of the world. This international, prospective, multicentre cohort study included consecutive patients undergoing elective or emergency gastrointestinal resection within 2-week time periods at any health-care facility in any country. Countries with participating centres were stratified into high-income, middle-income, and low-income groups according to the UN's Human Development Index (HDI). Data variables from the GlobalSurg 1 study and other studies that have been found to affect the likelihood of SSI were entered into risk adjustment models. The primary outcome measure was the 30-day SSI incidence (defined by US Centers for Disease Control and Prevention criteria for superficial and deep incisional SSI). Relationships with explanatory variables were examined using Bayesian multilevel logistic regression models. This trial is registered with ClinicalTrials.gov, number NCT02662231. Between Jan 4, 2016, and July 31, 2016, 13 265 records were submitted for analysis. 12 539 patients from 343 hospitals in 66 countries were included. 7339 (58·5%) patient were from high-HDI countries (193 hospitals in 30 countries), 3918 (31·2%) patients were from middle-HDI countries (82 hospitals in 18 countries), and 1282 (10·2%) patients were from low-HDI countries (68 hospitals in 18 countries). In total, 1538 (12·3%) patients had SSI within 30 days of surgery. The incidence of SSI varied between countries with high (691 [9·4%] of 7339 patients), middle (549 [14·0%] of 3918 patients), and low (298 [23·2%] of 1282) HDI (p<0·001). The highest SSI incidence in each HDI group was after dirty surgery (102 [17·8%] of 574 patients in high-HDI countries; 74 [31·4%] of 236 patients in middle-HDI countries; 72 [39·8%] of 181 patients in low-HDI countries). Following risk factor adjustment, patients in low-HDI countries were at greatest risk of SSI (adjusted odds ratio 1·60, 95% credible interval 1·05-2·37; p=0·030). 132 (21·6%) of 610 patients with an SSI and a microbiology culture result had an infection that was resistant to the prophylactic antibiotic used. Resistant infections were detected in 49 (16·6%) of 295 patients in high-HDI countries, in 37 (19·8%) of 187 patients in middle-HDI countries, and in 46 (35·9%) of 128 patients in low-HDI countries (p<0·001). Countries with a low HDI carry a disproportionately greater burden of SSI than countries with a middle or high HDI and might have higher rates of antibiotic resistance. In view of WHO recommendations on SSI prevention that highlight the absence of high-quality interventional research, urgent, pragmatic, randomised trials based in LMICs are needed to assess measures aiming to reduce this preventable complication. DFID-MRC-Wellcome Trust Joint Global Health Trial Development Grant, National Institute of Health Research Global Health Research Unit Grant.

1 April 2019 in Annals of Surgery
Verified
Journal Article
Closed access
ACAlexandre Challine
Alexandre Challine
CRClaire Rives-Langes
Claire Rives-Langes
DDDivya Danoussou
Divya Danoussou
SKSandrine Katsahian
Sandrine Katsahian
ABAmel Ait Boudaoud
Amel Ait Boudaoud
SCSébastien Czernichow
Sébastien Czernichow
Objective: The objective of the present study was to assess the effect of preoperative immunonutrition on a nationwide scale. Background: According to international guidelines, immunonutrition should be prescribed before major oncologic digestive surgery to decrease postoperative morbidity. Nevertheless, this practice remains controversial. Methods: We used a prospective national health database named “Echantillon généraliste des Bénéficiaires.” Patients were selected with ICD10 codes of cancer and digestive surgery procedures from 2012 to 2016. Two groups were identified: with reimbursement of immunonutrition 45 days before surgery (IN-group) or not (no-IN-group). Primary outcome was 90-day severe morbidity. Secondary outcomes were postoperative length of stay (LOS) and overall survival. Logistic regression and survival analysis adjusted with IPW method were performed. Results: One thousand seven hundred seventy-one patients were included. The proportion of different cancers was as follows: 72% patients were included in the colorectal group, 14% in the hepato-pancreato-biliary group, and 12% in the upper gastrointestinal group. Patients from the IN-group (n = 606, 34%) were younger (67.1 ± 11.8 vs 69.2 ± 12.2 years, P < 0.001), with increased use of other oral nutritional supplements (49.5% vs 31.8%, P < 0.001) and had more digestive anastomoses (89.4% vs 83.0%, P < 0.001). There was no significant difference between the 2 groups for 90-day severe morbidity [odds ratio (OR): 0.91, 95% confidence interval (95% CI): 0.73–1.14] or in survival (hazard ratio: 0.89, 95% CI: 0.73–1.08). LOS were shorter in the IN-group [−1.26 days, 95% CI: −2.40 to −0.10)]. Conclusion: The preoperative use of immunonutrition before major oncologic digestive surgery was not associated with any significant difference in morbidity or mortality. However, the LOS was significantly shorter in the IN-group.

1 December 2021 in Surgery
Verified
Journal Article
Closed access
ACAlexandre Challine
Alexandre Challine
BDBertrand Dousset
Bertrand Dousset
NDNicola De'Angelis
Nicola De'Angelis
JLJérémie H. Lefèvre
Jérémie H. Lefèvre
YPYann Parc
Yann Parc
ALAndrea Lazzati
Andrea Lazzati


12 August 2020 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
OBOlivier Benoit
Olivier Benoit
MSMagali Svrcek
Magali Svrcek
BCBen Creavin
Ben Creavin
MBMorgane Bouquot
Morgane Bouquot
ACAlexandre Challine
Alexandre Challine
JLJérémie Lefèvre
Jérémie Lefèvre

1 August 2021 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
ACAlexandre Challine
Alexandre Challine
TVThibault Voron
Thibault Voron
BDBertrand Dousset
Bertrand Dousset
BCBen Creavin
Ben Creavin
SKSandrine Katsahian
Sandrine Katsahian
JLJérémie Lefèvre
Jérémie Lefèvre